Humoral Response and SARS-CoV-2 Infection Risk following the Third and Fourth Doses of the BNT162b2 Vaccine in Dialysis Patients

The optimal SARS-CoV-2 vaccination schedule in dialysis patients and the potential need for a fourth vaccine dose are debatable. We prospectively assessed the humoral responses to three and four doses of BNT162b2 among dialysis patients. The study included 106 dialysis patients; 60 (56.6%) and 46 (4...

Descripción completa

Detalles Bibliográficos
Autores principales: Einbinder, Yael, Perl, Jeffrey, Nacasch, Naomi, Bnaya, Alon, Shavit, Linda, Erez, Daniel, Shashar, Moshe, Halperin, Tamar, Grupper, Ayelet, Benchetrit, Sydney, Wand, Ori, Cohen-Hagai, Keren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Novel Research Findings
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9501772/
https://www.ncbi.nlm.nih.gov/pubmed/35850101
http://dx.doi.org/10.1159/000525309
Descripción
Sumario:The optimal SARS-CoV-2 vaccination schedule in dialysis patients and the potential need for a fourth vaccine dose are debatable. We prospectively assessed the humoral responses to three and four doses of BNT162b2 among dialysis patients. The study included 106 dialysis patients; 60 (56.6%) and 46 (43.4%) received 3 and 4 vaccine doses, respectively. Anti-spike (anti-S) antibody titers significantly increased after the third vaccine dose, followed by a decline, yet still remained higher than all previous measurements. The fourth vaccine dose led to another profound rise in anti-S titers. The absolute increase following the fourth dose correlated with response to the third dose. Infection risk however was similar between patients vaccinated with three or four doses.

Ejemplares similares